On the rise
Imerys (+3%): The French mineral specialties giant benefits from the optimism of Berenberg, which maintains its buy recommendation and increases its price target from 45 to 47 euros. The German bank predicts an improvement in margins and favorable pricing dynamics from the fourth quarter, highlighting continued volume growth, particularly in the United States and Europe. It also anticipates a recovery in China.
Implantica (+6%): The stock is rising following the presentation of the new RefluxStop device at the AUGIS 2024 conference. Clinical trials reveal a significant improvement in the quality of life related to gastroesophageal reflux, with more than 90% improvement in scores after two years of use. These data confirm the efficacy and safety of the device, including for patients suffering from rare pathologies such as hiatal hernia, active esophagitis and Barrett’s esophagus.
Ubisoft Entertainment (+5%): The French video game publisher behind iconic games like Assassin’s Creed and Far Cry is encouraged by a rating from BMO Capital Markets. The broker raises its recommendation from “perform” to “outperform”, which is nevertheless accompanied by a reduced price target, from EUR27 to EUR22.
Down
Hexatronic Group AB (-11%): The Swedish distributor of fiber optic systems fell following the announcement of the departure of its CEO, Henrik Lyon, after a decade of good service. He will remain in office until his successor is appointed.
Davide Campari-Milano NV (-4%): The spirits producer was hit by the unexpected resignation of its CEO, Matteo Fantacchiotti, just five months after his appointment. The Italian group cited personal reasons for the sudden departure, without providing further details.
Beijer (-7%): The Swedish distributor of refrigeration and air conditioning products declined after its main shareholder, EQT, sold 20 million shares for SEK 3.3 billion. The transaction, led by Citi, Carnegie, Jefferies and Mizuho, was completed at a price 7.23% below the last closing price.
Novo Nordisk (-3%): The Danish lab expects its diabetes drug Ozempic to be on the list of treatments whose price will be negotiated downward by the U.S. government in 2027, Bloomberg reported. This anticipation is linked to the “Inflation Reduction Act” of 2022, which allows Medicare to negotiate the prices of expensive drugs for social coverage. The group has not yet made an official statement on the subject.
